drugset / Trial / NCT00386152
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Phase 2
Terminated
235 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ortho Biotech Clinical Affairs, L.L.C. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare hemoglobin response rates between two PROCRIT (epoetin alfa) doses and ARANESP (darbepoetin alfa) in anemic cancer patients receiving chemotherapy
Timeline
- Start
- 2006-11
- Primary completion
- 2008-03
- Completion
- 2008-05
Outcome
Outcome not reported
Stopped (Business): “No safety signals were noted. The study was stopped because it was no longer consistent with the company's scientific and strategic focus.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Darbepoetin alfa | Protein / enzyme biologic | 500 ug | Subcutaneous |
| Subject | epoetin alfa | Protein / enzyme biologic | 80000 iu | Subcutaneous |
| Subject | epoetin alfa | Protein / enzyme biologic | 120000 iu | Subcutaneous |